维罗纳制药 VRNA 深 沪
等待开盘 12-19 09:30:00 美东时间
106.91
0.000
0.00%
华盛通- 最 高--
- 今 开--
- 成交量 0股
- 最 低 --
- 昨 收 106.91
- 总市值 91.93亿
- 52周最高 106.93
- 市盈率 静 --
- 换手率 0.00%
- 52周最低 31.60
- 委 比 0.00%
- 总股本 8599.13万
- 历史最高 106.93
- 量 比 0
- 振 幅 0.00%
- 历史最低 2.01
- 每 手 1
- 风险率 21.79%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Oruka Therapeutics Announces New Board Member and Board Transition
Oruka Therapeutics announced the appointment of Chris Martin to its Board of Directors following Cameron Turtle's resignation. Martin, with over 25 years of commercial expertise, joins from Verona Pharma, where he successfully led the launch of a COPD treatment. His experience will aid Oruka in advancing its therapies for chronic skin diseases such as plaque psoriasis.
12-11 21:01
出海交易920亿美元！2025前三季度全球医药交易趋势总结
10月21日，中国创新药出海史诗再续震撼篇章——信达生物与武田制药达成超114亿美元战略合作，并且宣布携手在美国市场进行IBI363的商业化，振奋业界。据医药魔...
10-25 08:57
1.2万亿美元！强生、罗氏引领全球制药并购火力竞赛
（来源：医趋势） 进入2025年，全球制药行业的并购周期正在重新被点燃。专利悬崖逼近、创新竞争白热化、资本回流药企主业，叠加AI研发与新赛道崛起——资金雄厚的...
10-10 11:12
BD不BD，给个痛快吧
本文来自格隆汇专栏：阿基米德Biotech BD预期已形成堰塞湖。 恒生生物科技指数（HSHKBIO）在节日期间上涨3.7%，重燃创新药二次行情的希望，但在节后...
10-10 08:16
Next CDC AdCom meeting on vaccines delayed
The Centers for Disease Control and Prevention (CDC) has postponed an October meeting of its Advisory Committee on Immunization Practices (ACIP), an expert panel whose views are critical in the rollou...
10-09 19:17
1.2万亿美元！全球药企“氪金”榜单刷新！大扫货开始了
（来源：求实药社） 进入2025年，全球制药行业的并购周期正在重新被点燃。专利悬崖逼近、创新竞争白热化、资本回流药企主业，叠加AI研发与新赛道崛起——资金雄厚的...
10-09 12:05
Merck acquisition of Verona Pharma approved by court
Merck's (NYSE:MRK) ~$10B acquisition of Verona Pharma (NASDAQ:VRNA) has been granted approval by the High Court of Justice of England and Wales. Under terms, MSD, the trade name of Merck outside the U...
10-07 04:46
Verona Pharma Announces That High Court Of Justice Of England And Wales Has Approved Its Acquisition By MSD For $107 Per American Depository Share, Totaling ~$10B
Verona Pharma plc (NASDAQ:VRNA) ("Verona Pharma"), a biopharmaceutical company focused on respiratory diseases, which entered into a definitive agreement on July 8, 2025 relating to its proposed acquisition by MSD
10-07 04:07
Acquisition of Verona by MSD Approved by the High Court of Justice of England and Wales
Verona Pharma plc announced that the High Court of England and Wales has approved its acquisition by MSD for $107 per ADS, totaling approximately $10 billion. The transaction will close on October 7, 2025, upon the delivery of the Court Order to the Registrar of Companies. Trading of Verona ADSs on Nasdaq is expected to halt before October 7, 2025. The acquisition is implemented through a Court-sanctioned scheme of arrangement under English law.
10-06 20:05
